Evidence map›Paper›PMID 31455615›Full record

ArticleJournal of lipid research2019

Novel COX-2 products of

Ian de Bus, Han Zuilhof, Renger Witkamp, Michiel Balvers, Bauke Albada

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. PUFA-DerivedACS chemical biology · 2022
    Article
  3. Article
  4. Review
  5. Article
  6. The Biosynthesis of Enzymatically Oxidized Lipids.Frontiers in endocrinology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Ian de BusLaboratory of Organic Chemistry Wageningen University and Research, Wageningen, The Netherlands.ORCID 0000-0002-1061-8352
Han ZuilhofLaboratory of Organic Chemistry Wageningen University and Research, Wageningen, The Netherlands.ORCID 0000-0001-5773-8506
Renger WitkampNutritional Biology and Health Group, Division of Human Nutrition, Wageningen University and Research, Wageningen, The Netherlands.ORCID 0000-0002-7935-8261
Michiel BalversNutritional Biology and Health Group, Division of Human Nutrition, Wageningen University and Research, Wageningen, The Netherlands.ORCID 0000-0003-4308-3160
Bauke AlbadaLaboratory of Organic Chemistry Wageningen University and Research, Wageningen, The Netherlands bauke.albada@wur.nl.ORCID 0000-0003-3659-2434
Wageningen University & Research · NLTianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclooxygenase 2 (COX-2) plays a key role in the regulation of inflammation by catalyzing the oxygenation of PUFAs to prostaglandins (PGs) and hydroperoxides. Next to this, COX-2 can metabolize neutral lipids, including endocannabinoid-like esters and amides. We developed an LC-HRMS-based human recombinant (h)COX-2 screening assay to examine its ability to also convert

Indexed as

AnimalsCell SurvivalChromatography, LiquidCyclooxygenase 2EthanolamineFatty Acids, Omega-3LipopolysaccharidesMacrophagesMass SpectrometryMiceRAW 264.7 CellsRecombinant ProteinsCyclooxygenase 2EthanolamineFatty Acids, Omega-3LipopolysaccharidesRecombinant Proteinscyclooxygenasecyclooxygenase 2fatty acid amidesfatty acid oxidationhigh-performance liquid chromatographyinflammationmass spectrometryprostaglandins

Identifiers

PMID31455615
PMCPMC6824491
OpenAlexW2970466842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.